Yann‐Vaï Le Bihan

Institute of Cancer Research — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index650citations35works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(13), Ubiquitin and proteasome pathways(6), CAR-T cell therapy research(6), DNA Repair Mechanisms(5), Heat shock proteins research(4)

Publications35 total

Developing potent and selective TBK1 molecular glue degraders for cancer immunotherapy
2026Open Access
Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC <b>JB170</b> to <b>CCT400028</b> , an <i>In Vitro</i> Degrader Chemical Probe
Journal of Medicinal Chemistry·2026Open Access
Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening
Scientific Reports·2025Open Access
Discovery of first-in-class inhibitors of the TRF1-TIN2 protein-protein interaction by fragment screening
2025Open Access
Evaluating the impact of <i>CRBN</i> mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
Blood·2025· 6 citedOpen Access
Specific radiation damage to halogenated inhibitors and ligands in protein–ligand crystal structures
Journal of Applied Crystallography·2024· 2 citedOpen Access
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iScience·2024Open Access
Front Cover: A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity (ChemBioChem 23/2023)
ChemBioChem·2023Open Access
A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity**
ChemBioChem·2023· 15 citedOpen Access
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iScience·2023· 13 citedOpen Access
Discovery of an <i>In Vivo</i> Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones
Journal of Medicinal Chemistry·2023· 9 citedOpen Access
CCDC 2163947: Experimental Crystal Structure Determination
The Cambridge Structural Database·2022Open Access
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays
Scientific Reports·2022· 8 citedOpen Access
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors
Journal of Medicinal Chemistry·2022· 24 citedOpen Access
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>
Journal of Medicinal Chemistry·2022· 13 citedOpen Access
Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70
Molecules·2022· 7 citedOpen Access
Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket
Journal of Medicinal Chemistry·2021· 16 citedOpen Access
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
Leukemia·2021· 18 citedOpen Access
Mutations in <i>CRBN</i> and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models
Blood·2020· 2 cited
Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders
Journal of Medicinal Chemistry·2020· 72 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Rob L. M. van Montfort(21), Rosemary Burke(15), Craig McAndrew(15), Florence I. Raynaud(12), Angela Hayes(11), Olivier A. Pierrat(9), Benjamin R. Bellenie(8), Olivia W. Rossanese(8), Kwai-Ming J. Cheung(7), Owen A. Davis(7), Alan T. Henley(7), Rachel Talbot(7), Swen Hoelder(7), John Caldwell(7), Ian Collins(7), Michael D. Bright(6), Manjuan Liu(6), Rosemary Huckvale(6), Hannah Wang(6), Rajesh Chopra(6)